The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a https://mediajx.com/story26044855/retatrutide-vs-tirzepatide-a-comparative-analysis